NCT00451997View on ClinicalTrials.gov

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

August 31, 2005

Study Completion Date

April 30, 2007

Conditions
Leukemia, MyeloidMyelodysplastic Syndromes
Interventions
DRUG

Gleevec

600 mg (capsules) by mouth once daily

DRUG

Ara-C

10 mg as an injection under the skin daily for 21 days of every 28 day cycle

Trial Locations (1)

77030

The University of Texas M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER